prasugrel

Washington, February 4: Prasugrel, Eli Lilly & Company’s signature anti-clotting drug, Tuesday won the unanimous recommendation of a panel of experts for the U.S. Food and Drug Administration’s approval.

The drug now appears to be the first potential threat to Bristol-Myers Squibb’s Plavix, the world's second best selling drug.

Undergoing its pre-approval reviewing since last January, the drug was critically examined for its associated risk of internal bleeding. However, it was effective in correcting blood clots in patients with acute heart problems.

Washington, January 31: U.S. health regulatory officials declared Friday that the blood thinner, prasugrel jointly made by Eli Lilly and Co. and Daiichi Sankyo Co., Ltd. is more effec

“Superiority, not to a placebo, but to an active drug ..., prasugrel's efficacy seems beyond question," said United States Food and Drug Administration (FDA) staff reviewers, indicating approval.